Value proposition

Manufacturing Partner for Cell Therapy Process Development and Clinical Production

BioCentriq is an established, highly collaborative, global cell therapy CDMO. The company has been successfully manufacturing drug products for use in human clinical trials since 2022. In June of 2023, BioCentriq launched its LEAPTM Advanced Therapy Platform which helps cell therapy developers move from contract to clinic in as short as six months. With industry recognized scientists, engineers, analysts, and manufacturing specialists, established quality systems and modern infrastructure, BioCentriq is a proven strategic partner for the development and manufacturing of both autologous and allogeneic cell therapy products. The company was purchased by GC of South Korea for $73M in May 2022. On behalf of McKinsey, BioCentriq operates the only Innovation & Learning Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to life sciences. Visit www.biocentriq.com to learn more.

Cell therapy, clinical manufaturing, process development, Tech Transfer, Cell Banking, Upstream Processing, Downstream Processing, Monoclonal Antibodies, GMP Production, Cell Banking, Viral Banking, Allogeneic Cell Therapies, Autologous Cell Therapies, Workforce Development, and Corporate Training